Sun et al (2016) used a hepatocellular carcinoma cell line to show that treatment with ferroptosis-inducing compounds (e.g., erastin, sorafenib, and buthionine sulfoximine) upregulated NRF2 target genes via p62- and KEAP1-dependent regulatory pathways, contributing to ferroptosis resistance. Here, NFE2L2 is linked to hepatocellular carcinoma.